{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-027554","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.436477+00:00","generated_at":"2026-06-23T05:29:28.763633+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Interpace Biosciences CFO Thomas Freeburg resigns; continues as consultant and principal financial officer","bullets":["CFO Thomas Freeburg resigned effective Sept 30, 2022; will serve as consultant and acting principal financial officer until new CFO hired.","Severance of $127,500 (six months' base salary) payable over six months; equity awards scheduled to vest in 24 months fully accelerated.","Consulting fee of $6,000/month for up to 20% time (~8 hrs/week); term from Sept 30, 2022 to Jan 30–Mar 30, 2023.","Health and dental benefits continued for six months at Company expense; COBRA eligibility if elected.","Company actively recruiting a replacement CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-027554","json":"https://secwatch.observer/filing/0001493152-22-027554.json","markdown":"https://secwatch.observer/filing/0001493152-22-027554.md","text":"https://secwatch.observer/filing/0001493152-22-027554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/0001493152-22-027554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:29:28.763633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"361e0bcd6b","claim":"Thomas Freeburg resigned as Chief Financial Officer at INTERPACE BIOSCIENCES, INC..","evidence_excerpt":"On September 30, 2022 (the “Transition Date”), Thomas Freeburg, the Chief Financial Officer of Interpace Biosciences, Inc. ( the “Company”), resigned from his position as Chief Financial Officer and as an employee of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/0001493152-22-027554-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}